Salient Surgical Technologies of Portsmouth, NH, has raised $15 million in equity-based financing from a group of 10 unnamed investors, according to a regulatory filing published online yesterday. Established in 1999 and formerly known as Tissuelink Medical, Salient makes devices that stop bleeding and seal wounds by allowing surgeons to apply focused radio-frequency energy and saline solution to collagen fibers in the body. Salient raised $17.9 million in Series F funding in October 2008, with backing from, Piper Jafray Ventures, Arnerich Messina & Associates, Medtronic, and Rivervest Venture Partners; the Series F round came shortly after Salient withdrew plans for an $86 million initial public offering.
Wade Roush is Xconomy’s chief correspondent. You can e-mail him at email@example.com, call him at (617) 252-7323, or follow him on Twitter at http://twitter.com/wroush.